127 related articles for article (PubMed ID: 10854622)
21. The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol.
Dawson LA; Nguyen HQ
Neuropharmacology; 2000 Apr; 39(6):1044-52. PubMed ID: 10727715
[TBL] [Abstract][Full Text] [Related]
22. p-Chlorophenylalanine and fluoxetine inhibit D-fenfluramine-induced Fos expression in the paraventricular nucleus, cingulate cortex and frontal cortex but not in other forebrain and brainstem regions.
Javed A; Van De Kar LD; Gray TS
Brain Res; 1997 Nov; 774(1-2):94-105. PubMed ID: 9452197
[TBL] [Abstract][Full Text] [Related]
23. Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model.
Sghendo L; Mifsud J
J Pharm Pharmacol; 2012 Mar; 64(3):317-25. PubMed ID: 22309263
[TBL] [Abstract][Full Text] [Related]
24. Neurobiological changes mediating the effects of chronic fluoxetine on cocaine use.
Sawyer EK; Mun J; Nye JA; Kimmel HL; Voll RJ; Stehouwer JS; Rice KC; Goodman MM; Howell LL
Neuropsychopharmacology; 2012 Jul; 37(8):1816-24. PubMed ID: 22434223
[TBL] [Abstract][Full Text] [Related]
25. Fluoxetine suppresses morphine tolerance and dependence: modulation of NO-cGMP/DA/serotoninergic pathways.
Singh VP; Jain NK; Kulkarni SK
Methods Find Exp Clin Pharmacol; 2003 May; 25(4):273-80. PubMed ID: 12808472
[TBL] [Abstract][Full Text] [Related]
26. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability.
Curzon G; Gibson EL; Oluyomi AO
Trends Pharmacol Sci; 1997 Jan; 18(1):21-5. PubMed ID: 9114726
[TBL] [Abstract][Full Text] [Related]
27. Effects of fluoxetine or D-fenfluramine on serotonin release from, and levels in, rat frontal cortex.
Sarkissian CF; Wurtman RJ; Morse AN; Gleason R
Brain Res; 1990 Oct; 529(1-2):294-301. PubMed ID: 1704283
[TBL] [Abstract][Full Text] [Related]
28. Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertraline.
Garattini S; Bizzi A; Caccia S; Mennini T
Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 3():S43-50. PubMed ID: 1338321
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: evidence for the involvement of both 5-HT1A and 5-HT1B/D autoreceptors.
Barton CL; Hutson PH
Synapse; 1999 Jan; 31(1):13-9. PubMed ID: 10025679
[TBL] [Abstract][Full Text] [Related]
30. Selective effects of CGS 10686B, dl-fenfluramine or fluoxetine on nutrient selection.
Kim SH; Wurtman RJ
Physiol Behav; 1988; 42(4):319-22. PubMed ID: 2838855
[TBL] [Abstract][Full Text] [Related]
31. Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: short- and long-term memory.
Meneses A
Behav Brain Res; 2007 Nov; 184(1):81-90. PubMed ID: 17692935
[TBL] [Abstract][Full Text] [Related]
32. Fluoxetine attenuates the DL-fenfluramine-induced increase in extracellular serotonin as measured by in vivo dialysis.
Sabol KE; Richards JB; Seiden LS
Brain Res; 1992 Jul; 585(1-2):421-4. PubMed ID: 1511330
[TBL] [Abstract][Full Text] [Related]
33. Compensatory airway dilation and additive ventilatory augmentation mediated by dorsomedial medullary 5-hydroxytryptamine 2 receptor activity and hypercapnia.
Kanamaru M; Homma I
Am J Physiol Regul Integr Comp Physiol; 2007 Aug; 293(2):R854-60. PubMed ID: 17537836
[TBL] [Abstract][Full Text] [Related]
34. Persistent blockade of potassium-evoked serotonin release from rat frontocortical terminals after fluoxetine administration.
Gardier AM; Wurtman RJ
Brain Res; 1991 Feb; 540(1-2):325-30. PubMed ID: 1711396
[TBL] [Abstract][Full Text] [Related]
35. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac).
Leonardi ET; Azmitia EC
Neuropsychopharmacology; 1994 Jul; 10(4):231-8. PubMed ID: 7945733
[TBL] [Abstract][Full Text] [Related]
36. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex.
Invernizzi R; Bramante M; Samanin R
Pharmacol Biochem Behav; 1996 May; 54(1):143-7. PubMed ID: 8728551
[TBL] [Abstract][Full Text] [Related]
37. Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats.
Durkin S; Prendergast A; Harkin A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1894-901. PubMed ID: 18824064
[TBL] [Abstract][Full Text] [Related]
38. Neuropharmacological effects of low and high doses of repeated oral dexfenfluramine in rats: a comparison with fluoxetine.
Caccia S; Confalonieri S; Bergami A; Fracasso C; Anelli M; Garattini S
Pharmacol Biochem Behav; 1997 Aug; 57(4):851-6. PubMed ID: 9259015
[TBL] [Abstract][Full Text] [Related]
39. 1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain.
Baumann MH; Ayestas MA; Dersch CM; Rothman RB
Neuropsychopharmacology; 2001 May; 24(5):492-501. PubMed ID: 11282249
[TBL] [Abstract][Full Text] [Related]
40. Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse.
Knobelman DA; Hen R; Lucki I
J Pharmacol Exp Ther; 2001 Sep; 298(3):1083-91. PubMed ID: 11504805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
